SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Paul Senior who wrote (22315)10/21/2005 12:54:32 AM
From: Spekulatius  Read Replies (1) | Respond to of 78570
 
re PFE. I have made it an habit to sell first in the face of unexpected bad news and ask questions later. After some reflection about PFE's results I still think that this was the right decision. PFE revenue slide of 7% for the pharma sector is pretty shocking as is the loss of momentum for Lipitor sales.

Still PFE appears like a good value and I may consider a reentry after a 31 day cooloff period.



To: Paul Senior who wrote (22315)10/21/2005 8:47:58 AM
From: Suma  Read Replies (1) | Respond to of 78570
 
Hello nibbler...(:)

The report is that it will be one to three years before PFE has the variation of the current Lipitor that will enhance this premier cholesterol drug. I am 74 and hope that I live o long. Nothing to do now but hold I guess. Too big a loss to sustain selling now. My conundrum.. whether to average down again and get my price to $31.50

Good luck, Paul


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News